Targeted anti-cytokine therapy involves the use of an agent, such as a monoclonal antibody, that inhibits physiologic actions of the cytokine. Therapy reviewed here involved the use of an antibody to tumor necrosis factor, which has been used in a variety of inflammatory diseases, such as Crohn’s disease and arthritis. Use of this therapy was evaluated in patients with cancer for the management of fatigue.